ADD	Attention deficit disorder
ADHD	Attention deficit hyperactivity disorder
Amphetaminil	α-methylphenethyl(amino)phenylacetonitrile
BD	Bipolar disorder
Benzphetamine	N-benzyl-N,-dimethylphenethylamine
CBD	Cannabidiol
Clobenzorex	N-(2-chlorobenzyl)-amphetamine
CNS	Central nervous system
COMT	Catechol-O-methyl transferase
CUD	Cocaine use disorder
CYP	Cytocrome P450
d-ATS	Dextroamphetamine transdermal system
DAT	Dopamine transporter deficiencies
EMCDDA	European Monitoring Centre for Drugs and Drug Addiction
EROS	Extended-release oral suspension
FC	Functional connectivity
FDA	Food and Drug Administration
LC-NE	Locus coeruleus–norepinephrine
LDX	Lisdexamphetamine Dimesylate
LSD	Lysergic acid diethylamide
LTI	Life-threatening illness
MAS	Mixed amphetamine salts
MDA	3,4-methylenedioxyamphetamine
MDMA	3,4-methylenedioxymethamphetamine
NNT	Number needed to treat
PFC	Prefrontal cortex
PTG	Posttraumatic growth
PTSD	Post-traumatic stress disorder
PWS	Prader–Willi syndrome
SCT	Sluggish cognitive tempo
TEAE	Treatment-emergent adverse events
THC	Tetrahydrocannabinol
UNODC	United Nations Office on Drugs and Crime